Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

@article{Schneider2006EffectivenessOA,
  title={Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.},
  author={Lon S Schneider and Pierre N. Tariot and Karen Stevens Dagerman and Sonia M. Davis and John K. Hsiao and M. Saleem Ismail and Barry Lebowitz and Constantine G Lyketsos and J. Michael Ryan and T. Scott Stroup and David L. Sultzer and Daniel Weintraub and Jeffrey A. Lieberman},
  journal={The New England journal of medicine},
  year={2006},
  volume={355 15},
  pages={
          1525-38
        }
}
BACKGROUND Second-generation (atypical) antipsychotic drugs are widely used to treat psychosis, aggression, and agitation in patients with Alzheimer's disease, but their benefits are uncertain and concerns about safety have emerged. We assessed the effectiveness of atypical antipsychotic drugs in outpatients with Alzheimer's disease. METHODS In this 42-site, double-blind, placebo-controlled trial, 421 outpatients with Alzheimer's disease and psychosis, aggression, or agitation were randomly… 

Figures and Tables from this paper

Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.
TLDR
Cognitive function declined more in patients receiving antipsychotics than in those given placebo on multiple cognitive measures, including the MMSE, the cognitive subscale of the Brief Psychiatric Rating Scale, and a cognitive summary score summarizing change on 18 cognitive tests.
Atypical antipsychotic drugs and Alzheimer's disease.
TLDR
The adverse effects of atypical anti­ psychotic drugs for the treatment of psychosis, aggression, and agitation in patients with Alzheim­ er’s disease offset the advantages of these drugs.
Effect of second-generation antipsychotics on caregiver burden in Alzheimer's disease.
TLDR
In AD patients with symptoms of psychosis, agitation, or aggressive behavior, medications can have a small but significant impact on caregiver burden.
A Markov Model of the Cost Effectiveness of Olanzapine Treatment for Agitation and Psychosis in Alzheimer’s Disease
TLDR
OlanZapine treatment for agitation and psychosis related to Alzheimer’s disease is cost effective when compared with no treatment, and sensitivity analyses demonstrated that olanzapine remained cost effective despite multiple variations of several parameters, both alone and concurrently.
The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease.
TLDR
The use of antipsychotic medications, both conventional and atypical, was not associated with either time to nursing home admission or time to death after adjustment for relevant covariates, and the presence of psychiatric symptoms was linked to increased risk of institutionalization and death.
Atypical antipsychotics in the treatment of psychotic symptoms in Alzheimer’s disease: a systematic review
TLDR
Despite the consistent results present in the literature up to this point, various antipsychotics remain insufficiently studied and would need more generous sample sizes for their outcomes to be substantiated.
Management of psychosis in patients with Alzheimer’s disease: focus on aripiprazole
TLDR
These studies show improvement in the symptoms of psychosis associated with AD with aripiprazole and the safety and tolerability profile of aripIPrazole suggests a low potential for negative impact on dementia and overall patient health.
Use and Safety of Antipsychotics in Behavioral Disorders in Elderly People With Dementia
TLDR
Use of antipsychotics in dementia needs a careful case-by-case assessment, together with the possible drug-drug, drug-disease, and drug-food interactions.
Low Dose Lithium Treatment of Behavioral Complications in Alzheimer's Disease: Lit-AD Randomized Clinical Trial.
  • D. Devanand, E. Crocco, G. Pelton
  • Psychology, Medicine
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • 2021
Alternative pharmacological treatment options for agitation in Alzheimer’s disease
TLDR
Evidence coming from recently completed RCTs on novel or repositioned drugs showed some promise in treating agitation in AD, but still with safety concerns, with further evidence coming from ongoing Phase II and III trials on promising novel drugs.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 41 REFERENCES
Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.
  • L. Schneider, K. Dagerman, P. Insel
  • Psychology, Medicine
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • 2006
TLDR
Small statistical effect sizes on symptom rating scales support the evidence for the efficacy of aripiprazole and risperidone.
Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.
TLDR
Atypical antipsychotic drugs may be associated with a small increased risk for death compared with placebo, and this risk should be considered within the context of medical need for the drugs, efficacy evidence, medical comorbidity, and the efficacy and safety of alternatives.
Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients.
TLDR
Citalopram was found to be more efficacious than placebo in the short-term hospital treatment of psychotic symptoms and behavioral disturbances in nondepressed, demented patients.
Using antipsychotic agents in older patients.
TLDR
Recommendations concerning indications for antipsychotic use in older patients, choice of antipsychotics for different conditions, and Guidelines indicating preferred treatment strategies were developed for key clinical situations were developed.
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimer's Disease (CATIE-AD): baseline characteristics.
CATIE-AD was a multicenter effectiveness trial of atypical antipsychotics in patients with agitation and psychosis associated with AD who resided in the community. The study enrolled 421
Depression in Alzheimer’s disease: overview and treatment
The course of psychopathologic features in mild to moderate Alzheimer disease.
BACKGROUND The onset and course of the psychopathologic features of Alzheimer disease have not been established in prospective, longitudinal studies. METHODS Two hundred thirty-five patients with
A Metaanalysis of Controlled Trials of Neuroleptic Treatment in Dementia
TLDR
Clinically, neuroleptics treatment changed the improvement rate in agitated dementia patients from .41 to .59 (binomial effect‐size display), which indicates that 18 of 100 dementia patients benefited from neuroleptic treatment (beyond that of placebo) and is consistent with the modest efficacy described in previous qualitative reviews.
Anticonvulsant and Other Non-neuroleptic Treatment of Agitation in Dementia
TLDR
An overview of the assessment and management of agitation as it relates to the severity of dementia symptoms and cognitive deterioration is presented and the use of anticonvulsant and other non-neuroleptic therapies is examined.
Incidence of and risk factors for hallucinations and delusions in patients with probable AD
TLDR
A relatively high incidence of hallucinations and delusions in patients diagnosed with probable AD is found and it is suggested that specific neurologic signs, cognitive abilities, and accelerated decline may be predictive markers for their occurrence.
...
1
2
3
4
5
...